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ABSTRACT
It has been shown previously that cancer cells with an activated oncogenic 
pathway, including Met activation, require Ran for growth and survival.
Here, we show that knockdown of Ran leads to a reduction of Met receptor 
expression in several breast and lung cancer cell lines. This, in turn suppressed 
HGF expression and the Met-mediated activation of the Akt pathway, as well as cell 
adhesion, migration, and invasion. In a cell line model where Met amplification has 
previously been shown to contribute to gefitinib resistance, Ran knockdown sensitized 
cells to gefitinib-mediated inhibition of Akt and ERK1/2 phosphorylation and 
consequently reduced cell proliferation. We further demonstrate that Met reduction-
mediated by knockdown of Ran, occurs at the post-transcriptional level, probably via 
a matrix metalloproteinase. Moreover, the level of immunoreactive Ran and Met are 
positively associated in human breast cancer specimens, suggesting that a high level 
of Ran may be a prerequisite for Met overexpression. Interestingly, a high level of 
immunoreactive Ran dictates the prognostic significance of Met, indicating that the 
co-overexpression of Met and Ran may be associated with cancer progression and 
could be used in combination as a prognostic indicator.
INTRODUCTION
Ran GTPase (Ran) is a Ras-related protein that is 
involved in cell cycle regulation, nuclear-cytoplasmic 
transportation, and cell transformation [1, 2]. Recently, 
we and others have shown that Ran plays an important 
role in cancer cell survival and cancer progression [3–5]. 
Upstream factors that drive Ran expression and activity, 
and hence cause enhanced cell proliferation, cell survival, 
and cancer progression, have recently been identified and 
studied. These include the Ras and PI3K pathways [6], 
oesteopontin [7], RASSF1A [8], Sgk1 [9, 10] and Myc 
[11]. However, less is known of the downstream effectors 
of Ran.
The Met receptor has been shown to play an 
important role in both breast [12] and lung [13, 14] 
cancer. Cancer cells with Met amplification are addicted 
to Met for growth and survival [15]. Met overexpression is 
associated with resistance to trastuzumab and gefitinib in 
breast [16, 17] and lung [18, 19] cancer cells, respectively. 
Recently, Met overexpression has been shown to be 
associated with basal breast cancer [17, 20, 21], the most 
aggressive subtype of breast cancer, while chemical or 
biological inhibition of Met has been shown to reduce 
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breast cancer-derived bone metastasis [20]. In lung cancer, 
Met is a potential therapeutic target, and inhibitors of its 
tyrosine kinase activity together with anti-Met antibodies 
are being investigating in clinical trials [22, 23]. Indeed, 
Met expression has been shown to play an important role 
in other cancer type such as hepatocellular carcinoma [24].
Previously, a Ran binding protein, RanBPM, was 
shown to promote HGF-Met signaling [25], and we have 
shown that, in a rat cell line, Ran activates Met to promote 
cancer progression [7]. Nevertheless, to the best of our 
knowledge, there is no report describing the role of Ran 
in HGF-Met-mediated signaling in the progression of 
human cancer. Here, we show that Ran knockdown results 
in the reduction of Met, via post-transcriptional regulation, 
resulting in reduced responsiveness towards HGF-
stimulated biological properties associated with cancer 
progression, and sensitization of cells to gefitinib treatment.
RESULTS
Knockdown of Ran results in the down-
regulation of Met in multiple cancer cell lines
Previously, we have shown that knockdown of Ran 
using potent shRNA results in apoptosis [5]. To study 
the effect of Ran knockdown on cell properties without 
interference by apoptosis, a less potent shRNA was used, 
which was previously shown not to induce appreciable 
apoptosis even at 96 hours post-transfection, despite a 
significant reduction (~60%) in Ran expression [5]. Using 
this shRNA, we now find that knockdown of Ran in breast 
cancer cell lines MDA MB231 (Figure 1A), MCF10AT 
(Figure 1B) and MDA MB157 (Figure 1C)) and lung 
cancer cell lines (A549 (Figure 1D), H157 (Figure 1E) 
and H1299 (Figure 1F)) resulted in down-regulation of 
Met protein.
Knockdown of Ran reduces the responsiveness of 
cancer cells to HGF-induced phosphorylation of 
Met and Akt, but not of ERK1/2
As Met expression was reduced upon Ran 
knockdown, we next investigated whether this reduced 
Met signaling in both breast and lung cancer cell lines. 
Knockdown of Ran in both MDA MB231 breast and 
A549 lung cancer cells resulted in a reduction of the Met 
receptor in serum-free conditions (Figure 2). Treatment of 
cells with HGF for 30 – 60 minutes resulted in a dramatic 
induction of phosphorylation of Met and Akt but not of 
ERK1/2 (Figure 2). In contrast, Ran knockdown reduced 
Figure 1: Knockdown of Ran downregulates Met in multiple cell lines. Western blot for Ran, Met and Actin in breast cancer cell 
lines A. MDA MB231, B. MCF10AT and C. MDA MB157, and lung cancer cell lines D. A549, E. H157 and F. H1299.
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the HGF-mediated phosphorylation of Met and Akt in both 
cell lines (Figure 2). Again, phosphorylation of ERK1/2, 
which was not affected by HGF treatment, was not altered 
by Ran knockdown in the presence or absence of HGF 
in both cell lines (Figure 2). This result suggests that 
Ran knockdown specifically reduced the responsiveness 
towards HGF in terms of Met signaling in both breast 
(Figure 2A) and lung (Figure 2B) cancer cell lines.
Knockdown of Ran reduces the responsiveness 
of cancer cells to HGF-induced cell adhesion, 
migration, and invasion
Activation of Met signaling promotes invasive 
cancer growth [26, 27]. We therefore evaluated whether 
reduced Met signaling upon Ran knockdown causes a 
reduction in the aggressiveness of the cancer cells. HGF 
treatment of MDA-MB-231-shScr control cells resulted 
in a significant increase in cell adhesion (Figure 3A; 
Student’s t test at p < 0.05), migration (Figure 3B; p < 
0.05), and invasion (Figure 3C; p < 0.05). In contrast, 
treatment of Ran knockdown MDA MB231-shRan cells 
with HGF did not significantly alter cell adhesion (Figure 
3A); Student’s t test p < 0.05, migration (Figure 3B), or 
invasion (Figure 3C). Similarly, HGF treatment of lung 
cancer derived A549-shScr cells, but not A549-shRan 
cells, resulted in a significant increase in cell adhesion 
(Figure 3D; p < 0.05), migration (Figure 3E; p < 0.05), 
and invasion (Figure 3F; p < 0.05). Interestingly, Ran 
knockdown did not alter the cellular properties of A549 
cells in the absence of HGF, but did so in the presence 
of HGF (p<0.05) (Figure 3D–3F), suggesting that 
knockdown of Ran led to reduced cell adhesion, migration, 
and invasion only when Met signaling was activated. 
Figure 2: Knockdown of Ran reduces responsiveness of Met-Akt signalling to stimulation by HGF. Western blot for 
phospho-Met, total-Met, phospho-Akt, total-Akt, phospho-ERK1/2, total-ERK1/2, Ran, and Actin for A. MDA MB231 and B. A549 cells 
cultured in serum-free conditions in the presence or absence of HGF for 30 or 60 mins, 48 hour post-infection with shScr or shRan. Note 
that both Met and Akt phosphorylation were more prominently reduced by Ran knockdown in the presence of 10 ng/ml HGF in both cell 
lines.
Oncotarget4www.impactjournals.com/oncotarget
Collectively, our results suggest that Ran knockdown 
reduces the Met signaling-induced invasive properties of 
cancer cells in vitro.
Knockdown of Ran diminishes Met 
overexpression-mediated gefitinib resistance
Met overexpression in HCC827 GR5 lung cancer 
cells renders them insensitive to gefitinib-mediated 
inhibition of the PI3K/Akt and MEK/ERK pathways 
and gefitinib-induced apoptosis compared to HCC827 
parental cells [18]. Here, we investigated whether Ran 
knockdown sensitizes Met-overexpressing GR5 cells to 
gefitinib treatment. Gefitinib treatment of both HCC827-
shScr and HCC827-shRan inhibited Akt and ERK1/2 
phosphorylation (Figure 4A). In contrast in GR5-
shScr cells, phosphorylation of Akt and ERK1/2 was 
not significantly altered in the presence of up to 1 µM 
gefitinib (Figure 4A). However when Ran was knocked 
down in GR5-shRan cells, reduction in phosphorylation 
of both pAkt and pERK1/2 was observed in the presence 
of geftinib (Figure 4A). These results suggest that Ran 
knockdown sensitizes GR5 cells to gefitnib-mediated 
inhibition of both the PI3K/Akt and MEK/ERK pathways.
Similar to our previous study [5], when mediated by 
this less potent shRNA, knockdown of Ran did not alter 
the growth rate rate of HCC827 parental cells (shScr vs. 
shRan, Games-Howell post-hoc test, p = 0.158; Figure 
Figure 3: Knockdown of Ran reduces responsiveness of HGF-stimulated cell adhesion, migration, and invasion. 
A-C. MDA MB231 breast cancer cells transfected with either shScr or shRan were suspended in serum-free conditions in the presence or 
absence of 10 ng/ml HGF for the (A) adhesion, (B) migration, and (C) invasion assays. D-F. A549 lung cancer cells infected with either 
shScr or shRan were suspended in serum-free conditions in the presence or absence of HGF for the (A) adhesion, (B) migration, and (C) 
invasion assay.
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4B), but reduced the growth rate of HCC827 GR5 cells 
(shScr vs. shRan, Games-Howell post-hoc test, p = 0.044; 
Figure 4C). More importantly, the difference in the growth 
rate between the parental and GR5 cells and between 
shScr vs shRan was statistically significantly (p = 0.01), 
indicating that cancer cells with Met overexpression are 
more sensitive to Ran down-regulation.
HCC827 lung cancer cells were highly sensitive to 
gefitinib treatment, as both shScr (control vs. gefitinib, 
Games-Howell post-hoc test, p = 0.002 and p = 0.001, 
Figure 4: Knockdown of Ran sensitizes Met-overexpressing gefitinib-resistant lung cancer cells to gefitinib. A. Western 
blot for phospho-Akt, total-Akt, phospho-ERK1/2, total-ERK1/2, Ran, and Actin for HCC827 parental and GR5 cells in the presence or 
absence of 0.2 µM or 1 µM gefitinib. B-G. MTT growth assay for (B) HCC827 parental and (C) HCC827 GR5 cells infected with either 
shScr or shRan, (D) HCC827-shScr, (E) HCC827-shRan, (F) HCC827 GR5-shScr, and (G) HCC827 GR5-shRan cells with or without 
treatment with 0.2 µM or 1 µM gefitinib.
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for 0.2 µM gefitinib and 1 µM gefitinib, respectively; 
Figure 4D) and shRan transfected (control vs. gefitinib, 
Games-Howell post-hoc test, p = 0.002 and p = 0.001, 
for 0.2 µM gefitinib and 1 µM gefitinib, respectively; 
Figure 4E) HCC827 cells showed a significant reduction 
in growth upon gefitinib treatment. In contrast, HCC827 
GR5 was resistant to gefitnib treatment, with no significant 
inhibition of growth following exposure of GR5-shScr 
cells to 1 µM gefitinib (control vs. gefitinib, Games-
Howell post-hoc test, p = 0.461 and p = 0.227, for 0.2 
µM gefitinib and 1 µM gefitinib, respectively; Figure 4F). 
In contrast, knockdown of Ran in HCC827-GR5 cells 
resulted in their sensitization to gefitinib. Treatment of 
GR5-shRan cells with gefitinib resulted in a significant 
reduction in growth (control vs. gefitinib, Games-Howell 
post-hoc test, p = 0.167 and p = 0.008, for 0.2 µM 
gefitinib and 1 µM gefitinib, respectively; Figure 4G). 
The interaction among cell lines (HCC827 parental vs. 
GR5), shRNAs (shScr vs. shRan) and treatment (control 
vs. 1µM gefitinib) was statistically significant (p = 0.048; 
Figure 4D-G), suggesting that Ran knockdown increases 
the sensitivity of HCC827-GR5 cells, but not HCC827 
parental cells to gefitinib treatment.
Reduction of Met expression by Ran knockdown 
involves a post-transcriptional step
To investigate how Ran knockdown contributes to a 
reduction in Met expression, we first investigated whether 
it occurs at a transcriptional level. Using real-time PCR, 
we found that levels of Met mRNA were not significantly 
different between MDA MB231-shScr and MDA MB231-
shRan cells (Figure 5A). In other systems Met expression was 
previously shown to be regulated at the post-transcriptional 
level by either caspases [28, 29], via proteasome degradation 
[30, 31], or by metalloproteinase digestion [32, 33]. In the 
present study, we found the reduction in Met expression by 
Ran knockdown was not diminished by ZVAD and MG132 
treatment in both breast (MDA MB231; Figure 5B, left panel) 
and lung (A549; Figure 5B, right panel) cancer cell lines, 
indicating that caspase and proteasome degradation were not 
involved in the reduction in levels of Met by Ran In contrast, 
we found that treatment with GM6001, a metalloproteinase 
inhibitor, counteracted the downregulation of Met levels upon 
Ran knockdown in both MDA MB231 (Figure 5C, left panel) 
and A549 (Figure 5C, right panel) cancer cells. Collectively, 
our results suggest that the Ran knockdown-mediated 
reduction in Met expression occurs at the post-transcriptional 
level, and probably involves a metalloproteinase.
Relationship between Ran and Met expression in 
human breast cancer specimens
Amongst 247 human breast cancer specimens, 
71 contained less than 1% of cancer cells that 
immunohistochemically stained positive for Met, and 176 
specimens contained more than 1% of cancer cells that 
stained positive for Met. Only 23 out of 61 (37%) nuclear 
Ran negative specimens stained positive for Met, while 
significantly more nuclear Ran positive specimens (82%, 
153 out of 186) stained positive for Met (Fisher’s Exact 
test, p < 0.001; Figure 6A). Similarly, 62 out of 117 (53%) 
cytoplasmic Ran-negative specimens stained positive for 
Met, while significantly more cytoplasmic Ran-positive 
specimens (88%, 114 out of 130) stained positive for Met 
(Fisher’s exact test, p < 0.001; Figure 6B). Similar results 
were obtained when analyzing the association between 
overall nuclear and cytoplasmic Ran staining and Met 
staining in these human breast cancer specimens (p < 
0.001; Figure 6C). Together, our results suggest that Ran 
expression and Met expression were positively associated 
in human breast cancer specimens, in agreement with the 
in vitro data presented above.
Met expression is only associated with shorter 
survival time in those breast cancer patients with 
Ran-positive tumors
In the whole breast cancer patient cohort, high 
immunohistochemical staining for Met was significantly 
associated with shorter patient survival times (Wilcoxon-
Gehan test, p < 0.001; Figure 6D). However, when 
tumors were stratified according to immunohistochemical 
detection of Ran expression, this association was only 
significant in patients with a high level of immunoreactive 
Ran expression (Wilcoxon-Gehan test, p < 0.001; 
Figure 6E), and not in patients with low Ran expression 
(Wilcoxon-Gehan test, p = 0.052; Figure 6F).
DISCUSSION
In the present study, we have shown that Ran 
knockdown reduces Met protein levels, probably via 
metalloproteinase. The reduction in Met results in a 
reduced responsiveness of cancer cells to HGF, including 
PI3K/Akt activation downstream of Met and cellular 
properties associated with metastatic potential that 
are enhanced by HGF stimulation. Met reduction by 
knockdown of Ran in Met-overexpressing, gefitinib-
resistant lung cancer cells sensitizes the cells to gefitinib. 
Moreover, an association between immunohistochemical 
staining for Ran and Met was also observed in human 
breast cancer specimens, and an association between 
staining for Met and patient survival was only found 
in patients with tumors showing high levels of 
immunoreactive Ran. Our findings show for the first time 
a signalling link between Ran and Met, and the potential 
role of Ran as a therapeutic target for cancers addicted to 
Met signaling, including Met resistant cancers.
Previously, we and others have shown that k-Ras 
mutant [5, 34], PTEN-deleted [5], Met [5], and Myc [11] 
overexpressing cancer cells are more sensitive to Ran 
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knockdown compared to their wild-type counterparts, 
suggesting that Ran may be a potential therapeutic target 
for cancers with these oncogenic mutations. Met receptor 
is a promising therapeutic target in multiple cancer types 
[35], especially non-small cell lung cancer, in which Met 
overexpression has recently been shown to contribute to 
EGFR TKI resistance, including resistance to gefitinib 
[18] and erlotinib [36]. To counter this resistance, several 
agents have been investigated in clinical trials [22] 
including tivantinib [37], a tyrosine kinase inhibitor, and 
MetMab [38], a monovalent antibody targeting the Met 
receptor, both of which are highly anticipated drugs that 
are currently being tested in clinical trials in lung cancer. 
In the present study, we have shown that Ran knockdown 
results in the down-regulation of Met and reduced Met-
induced metastatic potential and gefitinib resistance, 
identifying a novel and additional role for Ran knockdown 
as a potential therapeutic approach for cancers addicted 
to Met signaling, including those cancers with acquired 
resistance to EGFR TKIs.
Figure 5: Ran knockdown-mediated Met downregulation occurs post-transcriptionally. A. Real-time PCR of Met in MDA 
MB231-shScr and MDA MB231-shRan cells. B. Western blot for Met, Ran, and Actin in MDA MB231 breast (Left) in A549 lung (Right) 
cancer cells transfected with either shScr or shRan with or without treatment with DMSO as control vehicle, MG132 (Proteasome inhibitor) 
10 µM and Caspase Inhibitor Z-VAD-FMK (20µM). C. Western blot for Met, Ran, and Actin in MDA MB231 breast (Left) and in A549 
lung (Right) cancer cells infected with either shScr or shRan or GM6001 (a metalloprotease inhibitor).
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Although we have shown that Ran knockdown-
mediated reduction in Met is a general phenomenon 
occurring in all 7 of the cell lines tested, including 3 
breast and 4 lung cancer cell lines, and that there is an 
association between Ran and Met expression, it remains 
unclear how Ran knockdown reduces the level of Met 
receptor in human breast cancer. A transcriptional process 
may be involved since Ran regulates transportation of 
transcription factors into the nucleus [39], and reduced 
import of a transcriptional activator of Met expression 
Figure 6: Relationship between tumor staining for Ran and Met tumor survival in breast cancer patients. A-C. The 
association between immunohistochemical staining for Ran and Met in human breast cancer specimens. (A) A high level of staining for 
nuclear Ran in tumors was significantly associated with a high level of Met staining (Fisher’s Exact test, p < 0.001). (B) A high level of 
cytoplasmic Ran staining was significantly associated with a high level of staining for Met (Fisher’s Exact test, p < 0.001). (C) A high level 
of staining for Ran was significantly associated with a high level of staining for Met when analyzing all specimens (Fisher’s Exact test, p < 
0.001). D-F. Relationship between tumor staining for Met and survival time in human breast cancer specimens. (D) Kaplan-Meier plot and 
wilcoxon-Gehan statistics showed that positive staining for Met expression was significantly associated with a shorter survival time in the 
breast cancer patient cohort ( χ2 = 47.964, 1 df, ρ<0.001). (E) Kaplan-Meier plot and wilcoxon statistics showed that a high level of staining 
for Met was significantly associated with a shorter survival time in breast cancer patients with positive staining of Ran in the primary tumors 
( χ2 = 17.307, 1 df, ρ<0.001). (F) Kaplan-Meier plot and Wilcoxon statistics showed staining for Met was not significantly associated with 
survival time in patients with low Ran expression in the primary tumors (χ2 = 3.774, 1 df, ρ=0.052).
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could be a possible explanation for the reduction in 
Met after Ran knockdown. However, in this study we 
found that the level of mRNA expression of Met was 
not different after Ran knockdown, suggesting that the 
reduction in Met occurs post-transcriptionally. Previous 
findings in other systems suggested that caspases [28, 
29], the proteasome [30, 31], or metalloproteinase [32, 
33] may mediate the interaction between Ran and Met. 
Our results support the last possibility, since inhibition 
of metalloproteinase by GM6001 restored the level of 
Met in Ran knock-down MDA MB231 and A549 cells. 
However, the exact metalloproteinase(s) involved 
have yet to be identified. Since metalloproteinases 
can be regulated via enzyme activation and inhibition, 
complex formation, and compartmentalization [40], it is 
quite possible that the intermediate metalloproteinases 
that act(s) between Ran and Met may not be regulated 
transcriptionally, and the identification of this 
metalloprotease is important to further our understanding 
of the interaction between Ran and Met and to provide 
a further therapeutic target for Ran-related neoplastic 
disease.
MATERIALS AND METHODS
Cell lines, plasmids, transfection, and viral 
infection
The MDA MB231 and MDA MB157 breast cancer 
cell lines, the A549 lung cancer cell line (ATCC), and 
the viral packaging 293T cell line were maintained in 
DMEM supplemented with 10% (v/v) fetal bovine serum 
and antibiotics. H157, H1299, HCC827 parental, and the 
Met overexpressing HCC827-GR5 lung cancer cell lines 
(ATCC). HCC827-GR5 was gift from Prof Pasi Janneand 
developed to be resistant to Gefitinib by amplification of 
Met gene were maintained in RPMI supplemented with 
10% (v/v) fetal bovine serum and antibiotics. The Ras-
transformed MCF10A derivative MCF10AT cell line (from 
Karmanos Cancer Centre, Detroit, MI) was maintained 
in DMEM/F-12 containing 5% horse serum, 10 μg/ml 
insulin, 20 ng/ml EGF, 100 ng/ml (v/v) choleratoxin, and 
0.5 μg/ml hydrocortisone.
Transfection was performed using GeneJuice® 
(Promega, Southampton, UK) according to the 
manufacturer’s instructions. pLKO.1-shScr and pLKO.1-
shRan5 (CCGGCAGTTCAAACTTGTATTGGTTCTCG
AGAACCAATACAAGTTTGAACTGTTTTTTG; Sigma-
Aldrich, Dorset, UK) were used for to knockdown Ran by 
Lentiviral infection, as previously described [5].
Real-time polymerase chain reaction
RNA was extracted using Trizol (Invitrogen, Paisley, 
UK) and reverse transcription was performed using 
SuperScriptTM III first strand synthesis system (Invitrogen) 
according to the manufacturer’s instructions. Real-time 
PCR was performed according to the manufacturer’s 
instructions (Applied Biosystem, Foester City, CA) using 
a Taqman® assay for Met (Hs01565581_m1, Applied 
Biosystem).
Western blot analysis
Western blotting was performed as previously 
described [5]. Briefly, cells were lysed in RIPA buffer 
containing protease inhibitors, and equal amounts 
of proteins were loaded onto a SDS-PAGE gel and 
transferred onto a nitrocellulose membrane (Millipore, 
Billerica, MA). The proteins of interest were then 
detected using specific primary antibodies against 
phospho-Met (Tyr1359), total-Met, phospho-Akt 
(Tyr 473), total-Akt, phospho-ERK, total-ERK (Cell 
Signaling, Danvers, MA), and Ran (Millipore) were used 
at 1:1000 dilution, while anti-Actin (Sigma) was used at 
1:10000 dilution.
MTT growth assay
Cells were seeded at a density of 3000 cells/well in a 
96-well plate in triplicate. Cells were allowed to grow for 
24 hours and drugs were then applied to the cells. MTT 
uptake by the cells was measured at 24, 48, 72 and 96 
hours post-treatment.
Boyden chamber migration and invasion assays
Migration and invasion assays were performed as 
previously described [41]. Briefly, 5000 and 50000 cells 
in serum-free conditions were seeded into the upper 
chamber (Millipore) on top of the membrane with or 
without Matrigel coating, respectively, for migration and 
invasion assays. The cells were allowed to migrate or 
invade towards the bottom layer with 10 ng/ml HGF as 
a chemoattractant for 24 hours. Cells in the bottom of the 
membrane were fixed and stained with crystal violet.
Cell adhesion assay
For the cell the adhesion assay, 40000 cells/well in 
suspension in serum-free conditions with or without 10 
ng/ml HGF were seeded in a 96-well plate coated with 
fibronectin and allowed to settle for 30 min. Suspended 
cells were removed by washing 4 times with PBS. 
Adhered cells were fixed and stained with crystal violet. 
The excess dye was washed out and the retained dye was 
extracted. The absorbance at 595nm was measured in a 
microplate reader.
Patients and breast cancer specimens
Patients and specimens were described previously 
[5].
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Immunohistochemical staining and evaluation
Immunohistochemical staining and evaluation of the 
staining was performed as previously described [5].
Statistical analysis
Statistical analysis was performed using SPSS 19.0 
software. Differences in expression levels between groups/
samples were analyzed by Fisher’s Exact test. Survival 
analysis was performed using Kaplan-Meier plots and 
differences were tested using Wilcoxon-Gehan statistics. A 
p-value of <0.05 was considered significant in all statistical 
analyses.
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